Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.
Loustaud-Ratti
V
V
Service de Médecine Interne et Fédération des Hépatites, CHU Dupuytren, 87042 Limoges cedex, France. veronique.loustaud-ratti@unilim.fr
Stanke-Labesque
F
F
Marquet
P
P
Gagnieu
M-C
MC
Maynard
M
M
Babany
G
G
Trépo
C
C
D000740:Anemia / Q000139:chemically induced; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
D000998:Antiviral Agents; D012254:Ribavirin